HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) - A Strong Candidate for Affordable Growth Investors

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) stands out as an affordable growth stock based on our screening criteria. The company combines strong growth prospects with reasonable valuation metrics, while maintaining solid financial health and profitability.

Growth Prospects

HRMY demonstrates impressive growth, scoring a 9 out of 10 in our growth rating. Key highlights include:

• Revenue Growth: Over the past year, revenue increased by 20.62%, with an average annual growth rate of 160.13% in recent years.
• Earnings Expansion: Earnings per share (EPS) have grown by 44.61% on average annually.
• Future Expectations: Analysts project continued strong growth, with EPS expected to rise by 36.90% and revenue by 21.10% annually in the coming years.

Attractive Valuation

With a valuation rating of 9, HRMY appears reasonably priced:

• P/E Ratio: At 12.74, it trades below both the industry average (19.28) and the S&P 500 (24.85).
• Forward P/E: The forward P/E of 7.79 suggests further upside potential.
• Price-to-Free Cash Flow: HRMY is cheaper than 92.42% of its pharmaceutical peers based on this metric.

Financial Health and Profitability

The company maintains strong financials:

• Health Rating (8/10): A low debt-to-equity ratio (0.22) and high liquidity (current ratio of 3.67) indicate financial stability.
• Profitability (7/10): HRMY boasts a 20.50% profit margin and a 28.48% operating margin, outperforming most industry peers.

For a deeper look, review the full fundamental analysis of HRMY.

Our Affordable Growth screener lists more stocks with similar characteristics and is updated daily.

Disclaimer

This is not investing advice! The article highlights observations at the time of writing, but you should conduct your own analysis before making investment decisions.